CLINICAL TRIALS PROFILE FOR IRSOGLADINE
✉ Email this page to a colleague
Clinical Trials for Irsogladine
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02581696 ↗ | The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers | Completed | The Catholic University of Korea | Phase 1 | An open-label, multiple-dose, single-arm, phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers |
| NCT02581696 ↗ | The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers | Completed | Boryung Pharmaceutical Co., Ltd | Phase 1 | An open-label, multiple-dose, single-arm, phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers |
| NCT02759224 ↗ | A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet | Completed | Boryung Pharmaceutical Co., Ltd | Phase 1 | An Open-Label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics of BRI-1501 Tablet and Coadministration of Lafutidine and Irsogladine maleate as Individual Tablets in Healthy Adult Volunteers |
| NCT03509831 ↗ | [KJ-INT-002] BE Study | Unknown status | Kukje Pharma | Phase 1 | Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 after Oral Administration to Healthy Adult Male Subjects |
| NCT05249725 ↗ | Therapeutic Effect of Isoladine Maleate on Small Intestinal Mucosal Injury Associated With NSAIDS in Population | Not yet recruiting | Lee's Pharmaceutical Limited | Phase 4 | All patients who met the inclusion criteria and agreed to participate in the study underwent baseline capsule endoscopy. Patients with intestinal mucosal injury detected during the initial capsule endoscopy were randomly divided into isoladin maleate group or magnesium aluminum carbonate control group using computer-generated random numbers. Patients in the isoladine maleate group received 4 mg isoladine maleate (Gesellon, Japan) every morning for 4 weeks (or 8 weeks, duration to be determined); Magnesium aluminum carbonate control group received 1 g magnesium aluminum carbonate every morning, afternoon and evening for 4 weeks (or 8 weeks, course to be determined). After treatment, capsule endoscopy was performed again to evaluate the healing of intestinal mucosa. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Irsogladine
Condition Name
Clinical Trial Locations for Irsogladine
Clinical Trial Progress for Irsogladine
Clinical Trial Phase
Clinical Trial Sponsors for Irsogladine
Sponsor Name
